Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood Glucose Monitoring, Hematology, Tumor), Sample Type (Blood, Urine), and End User—Global Forecast to 2030

Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood Glucose Monitoring, Hematology, Tumor), Sample Type (Blood, Urine), and End User—Global Forecast to 2030

Point-of-Care Diagnostics Market by Platform (LFA, Molecular), Application (TB, Pneumonia, Salmonellosis, Hepatitis, HIV, COVID-19, Pregnancy, Blood Glucose Monitoring, Hematology, Tumor), Sample Type (Blood, Urine), and End User—Global Forecast to 2030

The global point-of-care diagnostics market is projected to reach $43.1 billion by 2030, at a CAGR of 5.1% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth in the point-of-care diagnostics market is mainly attributed to the rapidly growing demand for cost-efficient PoC tests, the outbreak of COVID-19, and growing funding for PoC diagnostics tests. However, pricing pressure due to fluctuations in reimbursements restrains the growth of this market. Increasing demand for PoC diagnostics in emerging economies is expected to create opportunities in the market.

Based on offering, in 2023, the consumables segment is expected to account for the largest share of the market. Diagnostic kits are designed to provide highly accurate results with minimal risk of user error. They are pre-packaged with all the necessary materials and reagents, ensuring that the correct amounts are used, thus reducing the risk of contamination, contributing to the segment's largest share.

Based on platform, the molecular diagnostics segment is projected to register the highest CAGR during the forecast period. The tests are commonly used for the detection of viruses such as COVID-19 and flu, while LAMP tests are used for the detection of bacteria and viruses, such as tuberculosis and human papillomavirus (HPV). These tests can provide results within 30 minutes to an hour, depending on the complexity of the test and the type of instrument used. The shorter turnaround time of test results drives the market for molecular diagnostics.

Based on application, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the global point-of-care diagnostics market. PoC devices are widely used for monitoring blood glucose levels. These devices offer reliable quantitative results and are portable, inexpensive, and easy to use, driving the segment growth. Additionally, they enable healthcare professionals to make immediate treatment decisions in response to glycemic fluctuations in hospitalized patients and can also be used by diabetic patients at home to monitor their glucose levels frequently.

Based on sample type, in 2023, the blood sample type segment is expected to account for the largest share of the global point-of-care diagnostics market. Blood sample testing has many benefits, such as determining infections and risks for various health conditions, monitoring the status and progression of chronic diseases, checking treatment success, and in some cases, early disease diagnosis, contributing to the largest share of the segment.

Based on end-user, in 2023, the hospital segment is expected to account for the largest share of the global point-of-care diagnostics market. Hospitals perform various tests to diagnose medical conditions and ensure proper clinical treatment and prevention planning. Factors such as the urgency in medical decision-making, increasing healthcare expenditure, rising prevalence of healthcare-associated infections (HAIs), and the rising number of hospitals and clinics across emerging markets are driving the demand for point-of-care diagnostic kits for use in hospitals & clinics.

An in-depth analysis of the geographical scenario of the global point-of-care diagnostics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the point-of-care diagnostics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America’s large share is attributed to the region’s highly developed diagnostics infrastructure, the trend of PoC testing, the high prevalence of chronic diseases coupled with growth in the aging population, the rising number of inpatient admissions, and the high adoption of self-testing kits among the general population.

The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).

Scope of the Report:

Point-of-Care Diagnostics Market Assessment—by Offering

Consumables
Instruments
Software and Services

Point-of-Care Diagnostics Market Assessment—by Platform

Lateral Flow Assays
Molecular Diagnostics
Other Platforms

(Other platforms include coagulation tests, dipsticks, cholesterol and glucose monitoring systems, and other point-of-care diagnostic platforms)

Point-of-Care Diagnostics Market Assessment—by Application

Blood Glucose Monitoring
Infectious Disease Testing
Parasitic Infection Testing
Blood-borne Infection Testing
Hepatitis
HIV
Other Blood-borne Infections
Respiratory Infection Testing
Influenza
Pneumonia
Other Respiratory Infection Testing
Healthcare-associated Infection (HAI) Testing
Gastrointestinal (GI) Infection Testing
Salmonellosis
E. Coli Infections
Other GI Infections
Other Infectious Disease Testing
COVID-19 Testing
Tumor/Cancer Markers Testing
Pregnancy And Fertility Testing
Pregnancy Testing
Fertility Testing
Cardiac Marker/Cardiac Metabolism Testing
Cholesterol/Lipid Profile Testing
Coagulation Testing
Prothrombin Time (PT/INR) Testing
Activated Clotting Time (ACT/APTT) Testing
Other Coagulation Testing
Hematology
Drugs Of Abuse Testing
Urinalysis
Other PoC Testing

(Other respiratory infections testing include strep infections and respiratory syncytial virus (RSV). Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis. Other blood-borne diseases include syphilis and brucellosis. Other infectious disease testing includes meningitis, hand, foot, and mouth disease (HFMD), and mononucleosis. Other coagulation testing includes fibrinogen level and platelet count. Other PoC testing includes tropical diseases and sexually transmitted diseases)

Point-of-Care Diagnostics Market Assessment—by Sample Type

Blood Sample
Nasopharyngeal swab
Urine Sample
Saliva Sample
Other Sample Types

(Other sample types include stool, cervical swab, buccal swab, hair, vaginal swab, and semen)

Point-of-Care Diagnostics Market Assessment—by End User

Hospitals
Home care/self-testing
Physician Offices & Ambulatory Care Settings
Diagnostics Laboratories
Other End User

(Other end users include nursing homes, long-term care centers, pharmacies, urgent care facilities, schools, airports, hotels, and workplaces)

Point-of-Care Diagnostics Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Rest of Latin America
Middle East & Africa

PoC Diagnostics Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	395
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Market by Platform, Market by Application, Market by Sample Type, Market by End User, Market by Geography
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).

FAQs About the Report

What is the focus of the point-of-care diagnostics market?

The point-of-care diagnostics market study covers the market sizes & forecasts for various point-of-care diagnostic products used in the healthcare sector. The report involves the value chain analysis of various segments and subsegments of the point-of-care diagnostics market at the regional and country levels.

What is the value of revenue generated from point-of-care diagnostics tests across the globe?

The global point-of-care diagnostics market is projected to reach $43.1 billion by 2030, at a CAGR of 5.1% during the forecast period.

Which PoC diagnostic application segment is estimated to hold the major share of the market in 2023?

The blood glucose monitoring segment is expected to account for the largest share of the point-of-care diagnostics market in 2023. Factors such as the rising prevalence of diabetes, advancements in diagnostics products, and increasing awareness among the population for regular health checkups contribute to the large market share of this segment.

Which PoC diagnostic platform segment is estimated to hold the major share of the market in 2023?

Based on the platform, in 2023, the LAF segment is estimated to hold the major share due to factors such as their one-step process, long shelf life, higher portability & lower costs compared to laboratory-based tests.

Which sample type segment is projected to create more traction in the global PoC diagnostic market?

Based on sample type, the blood sample segment is projected to create more traction during the forecast period due to the availability of a wide range of tests that can be conducted using blood samples, the growing prevalence of chronic diseases, and an increasing awareness among consumers about the importance of self-monitoring.

Which end-user segment is estimated to hold the major share of the market in 2023?

Based on end user, in 2023, the hospitals segment is estimated to hold the major share due to an increasing patient inflow, well-established infrastructure, and technological advancements.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global PoC diagnostic market?

The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, the development of CLIA-waived PoC tests, and the lack of skilled technicians for performing lab tests. In addition, emerging markets and healthcare professionals’ increasing preference for PoC tests over lab tests are expected to offer significant market growth opportunities.

Who are the major players operating in the global PoC diagnostic market?

The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMérieux S.A. (France).

Which regions/countries will likely offer significant growth opportunities for the vendors in this market during the analysis period?

The emerging countries of Asia-Pacific are projected to offer significant growth opportunities for the vendors in this market due to the continuous improvement in the healthcare infrastructure, the rising number of hospitals, and growing government investment in this sector.